Cell Based Assays for Drug Discovery

Cell Based Assays for Drug Discovery ( )The4. Strategic Analysis of the High-Content Tools
term drug discovery tools usually refers toSpace 60
high-content screening (HCS) and analysis and is4.1 Analysis of the High-Content Market Structure
composed of those applications that require60
sufficient levels of sample throughput, whereby4.2 Description of the Drug Discovery Marketplace
complex cellular events and phenotypes can beand Definition of the Field 60
studied.4.3 Key Market Drivers and Challenges in the
Elements of drug performance like toxicity andHigh-Content Analysis Space 61
specificity can be established simultaneously using4.4 Consolidated Picture of the High-Content
mixed cell types—primary cells, cell lines, cellAnalysis Marketplace 65
subpopulations. HCS seeks to assess the impact4.5 High-Content Analysis Market Sectors and
of phenotypic and cellular changes that areGrowth Rate 66
brought about by gene modification (such as with4.6 Vendors of High-Content Analysis Technology
RNA interference (RNAi) approaches) and/or drug66
(or compound) treatment. The purpose of this5. High-Content Analysis Technology Platforms 67
examination  is to describe the specific segments5.1 Methods of Digital Imaging 67
of the global drug discovery tools market. Within5.2 Fluorescence Microscopy 67
this area, the report covers those segments that5.3 Major High-Content Analysis Instrumentation
are highly active in terms of innovation and68
growth. Specifically, this study examines the5.3.1 High-Content Analysis Platforms to Support
markets for small lab equipment all the way up toGPCR Screening 69
highly automated, large automated platforms, as5.4 High-Content Analysis Reagents 69
well as accessory equipment such as reagents,5.5 Imaging Software 70
supplies and manufacturers’ original equipment5.6 Enterprise-Level IT Solutions to Support
manufacturer (OEM) additional equipment.High-Content Screening Experiments 70
Table of Contents:5.6.1 Image Analysis Algorithms 71
1. Overview 55.7 Use of RNAi in High-Content Analysis 73
1.1 Objectives of the Report 55.8 Industry Alliances to Leverage RNAi and
1.2 Methodology 6High-Content Analysis 73
1.3 Scope of the Report 75.9 Emerging Trends in High-Content Analysis
1.4 Executive Summary 8Technology Platforms 74
2. Technologies and Product Offering for6. High-Content Analysis in Drug Selection,
High-Content Analysis 11Screening and Biomarker Discovery 75
2.1 Definition of High-Content Analysis and Why it6.1 Stem Cells as Tools for Drug Discovery 76
is so Attractive a Discipline 126.2 Cellular Systems Biology for Development of
2.2 Classes of Measurements Possible withToxicity Panels in Drug Safety Testing 76
High-Content Analysis Approaches and Biological6.3 Drug Discovery Companies Marketing
Functions Investigated 15Cell-based Assays 77
2.3 Instrumentation Platforms for High-Content6.4 Companies Using Cell-based Assays in Drug
Analysis 19Discovery Programs 80
2.3.1 High-Content Screening Technology 196.4.1 Phenotypic Drug Discovery (PDD) 80
2.4 Reagent and Assay Platforms for6.4.2 Application of Quantitative High-Throughput
High-Content Analysis 26Screening to HCA Cell-based Assays 80
2.5 Cell-based Screening Technologies in Drug6.4.3 Application of High-Content Fingerprinting to
Development 29Oncology Drug Discovery: Focus on in vitro and in
2.5.1 Applications of Cell-based Assays 30vivo Phenocopying and Cancer Stem Cell Analysis
2.5.2 Pharma Drug Discovery Paradigm and81
Compound Screening 306.5 Target Discovery and Validation by RNAi
2.5.3 High-Content Analysis in theScreening 81
Biopharmaceutical Industry 316.6 FLIM-FRET Methodology 81
3. Market Analysis of the High-Content Tools6.7 Multidimensional Fluorescence Imaging (MDFI)
Space 33Technology 81
3.1 High-Content Analysis Market Size and Growth7. Company Profiles 82
337.1 Acumen Pharmaceuticals, Inc. 82
3.2 Market Survey to Assess Qualitative and7.2 Acumen Bioscience (division of TTP Group) 82
Quantitative Parameters of the High-Content7.3 Applied Biosystems 82
Analysis Space 337.4 BD Biosciences 84
3.3 Experimental and Research Trends in7.5 DiscoveRX 84
High-Content Analysis 357.6 Evotec Technologies (acquired by PerkinElmer)
3.4 Challenges and Market Drivers in High-Content84
Analysis 407.7 Fisher BioImage 84
3.4.1 Barriers to High-Content Analysis 427.8 General Electric, GE Healthcare 85
3.4.2 Drivers of High-Content Analysis 437.9 Guava Technologies (now a division of Millipore)
3.5 High-Content Analysis in Combination with RNAi85
437.10 Integral Molecular (Akceli Inc.) 86
3.6 Market Landscape of Instrumentation for7.11 LemnaTech GmbH 86
High-Content Analysis 457.12 Millipore 86
3.7 Reagent and Assay Usage in High-Content7.13 Molecular Devices Corporation, now a division
Analysis 49of MDS Analytical Techniques 88
3.8 Trends in the High-Content Analysis Assays7.14 NIH Chemical Genomics Center 90
Reagents Space—Major Product Vendors 527.15 PerkinElmer 91
3.9 Emerging Market Trends in High-Content7.16 Sangamo Biosciences, Inc. 93
Analysis 547.17 Spotfire (acquired by TIBCO) 93
3.10 Market Forecasts for the High-Content7.18 Thermo Scientific Cellomics 94
Analysis Space 577.19 Translational Genomics Research Institute 94
3.11 Use of HCS in Pharmaceutical Companies 587.20 Vala Sciences, Inc. 94
3.12 Qualitative Opportunities and Challenges for8.
Market Adoption 59